Vaccine Presentation and Packaging Advisory Group (VPPAG)
Optimizing presentation and packaging for HPV vaccines
Working in collaboration with the Vaccine Presentation and Packaging Advisory Group (VPPAG), representatives from the public health community initiated a series of studies to guide presentation and packaging decisions for future iterations of Human Papillomavirus (HPV) vaccines destined for low-income countries. Presentation and packaging decisions, such as the number of doses per container, type of container, and recommended storage temperatures greatly impact the way vaccines are handled, the quantity of vaccine doses wasted, and the ability of health workers to get the vaccines to remote, low-resource settings. By influencing these decisions early in the development process, public health officials can make sure that the specific needs of developing countries are considered.
HPV vaccines present unique characteristics that differentiate them from currently World Health Organization (WHO) prequalified infant vaccines. HPV vaccines target an older, gender-specific population; are currently available at higher prices than most existing WHO-prequalified vaccines; offer promising heat-stability profiles; and similar to pneumococcal vaccines, are currently available only as liquid formulations without preservative.
Following is a list of studies undertaken to gather data from users, procurement specialists, and economists to better understand needs and constraints regarding HPV vaccines: